← Evidence map

ArticleCancers2026

Durable Progression-Free and Treatment-Free Survival After Nivolumab Plus Ipilimumab Therapy in Metastatic Renal Cell Carcinoma: A Real-World Study with a 5-Year Minimum Follow-Up.

Hiroaki Ikoma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Durable Progression-Free and Treatment-Free Survival After Nivolumab Plus Ipilimumab Therapy in Metastatic Renal Cell Carcinoma: A Real-World Study with a 5-Year Minimum Follow-Up. | OpenQuestion